Partner Therapeutics, Inc.
https://www.partnertx.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Partner Therapeutics, Inc.
Deal Watch: Lilly Sends European Commercial Rights For Two Migraine Drugs To Organon
Plus deals involving Biocytogen, Neurocrine and Ona, Aeterna Zentaris/Ceapro, Teva/Biolojic Design, Pathos AI/Rain Oncology, Inhibitor Therapeutics/Johns Hopkins and more.
Finance Watch: The Rush To End 2023 With Fresh VC Cash For Biopharma
Private Company Edition: Playground’s third fund has $410m for tech, including biotech, Pivotal Life Sciences closed its second fund with $389m and Chugai will invest $200m through its new fund. Also, Tome launched with $213m, Sudo raised a $116m series B and Odyssey closed a $101m in series C.
When You Can’t Win For Losing: Kodak And The Reshoring Of US Pharmaceutical Manufacturing
Kodak, Fujifilm and startups Civica Rx and Phlow fight with grit, vision and government support to restore US pharmaceutical manufacturing.
Finance Watch: Notable Neuroscience VC Deals Include Nura Bio’s $73m Launch
Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- PTx
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice